A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2009
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 25 Sep 2005 New trial record.